

## NANO EXPRESS

## Open Access



# Comparative Analysis of the Antineoplastic Activity of C<sub>60</sub> Fullerene with 5-Fluorouracil and Pyrrole Derivative In Vivo

O. V. Lynchak<sup>1\*</sup>, Yu I. Prylutsky<sup>1</sup>, V. K. Rybalchenko<sup>1</sup>, O. A. Kyzyma<sup>1,2</sup>, D. Soloviov<sup>2,3</sup>, V. V. Kostjukov<sup>4</sup>, M. P. Evstigneev<sup>4,5</sup>, U. Ritter<sup>6</sup> and P. Scharff<sup>6</sup>

## Abstract

The antitumor activity of pristine C<sub>60</sub> fullerene aqueous solution (C<sub>60</sub>FAS) compared to 5-fluorouracil (5-FU) and pyrrole derivative 1-(4-Cl-benzyl)-3-Cl-4-(CF<sub>3</sub>-phenylamino)-1H-pyrrol-2.5-dione (MI-1) cytostatic drugs was investigated and analyzed in detail using the model of colorectal cancer induced by 1.2-dimethylhydrazine (DMH) in rats. The number, size, and location of the tumors were measured, and the pathology was examined. It was found that the number of tumors and total lesion area decreased significantly under the action of C<sub>60</sub>FAS and MI-1. Because these drugs have different mechanisms of action, their simultaneous administration can potentially increase the effectiveness and significantly reduce the side effects of antitumor therapy.

**Keywords:** C<sub>60</sub> fullerene, 5-Fluorouracil, Pyrrole derivative, Colorectal cancer, Small-angle X-ray scattering, Molecular modeling

## Background

C<sub>60</sub> fullerene has been intensively investigated in the last decades mainly because of their vast range of potential applications in nanotechnology. The nearly spherical C<sub>60</sub> molecule (diameter is 0.72 nm) can currently be routinely synthesized and is characterized by high chemical stability and biological activity in vitro and in vivo [1–4]. C<sub>60</sub> fullerenes are soluble in nonpolar organic solvents [5] and can be transferred into the water by means of special procedures [6–8]. These properties enable fullerene to utilize in biological objects due to their ability to easily penetrate the cell lipid membrane [9–12]. At low (near-physiological) concentrations, C<sub>60</sub> fullerenes demonstrate no acute toxic effect in normal cells [13–17]. It was also reported that C<sub>60</sub> fullerene can be used in anti-tumor therapy [18, 19], including the photodynamic therapy for the treatment of oncological diseases [20–23] as well as the targeted delivery of traditional drugs into cancer cells [24, 25].

Colon cancer (colorectal cancer) is one of the most common diagnoses in the world, which corresponds to approximately 1.4 million patients in 2012, and this number is foreseen to increase by almost half in 2035 [26, 27]. The 5-year relative survival rate for patients with colorectal cancer is in between 12 and 90% and strongly depends on the time passed till diagnosis, the stage of the disease, and the conducted treatment [28].

Colorectal carcinogenesis is a heterogeneous and complex multistage process, which involves violations of a homeostatic control of proliferation, differentiation, and apoptosis of intestine epithelial cells. The causes of these disorders are genetic mutations of transforming oncogenes and deletions or mutations of DNA repair genes and tumor suppressor genes. In addition, indirectly acting factors, such as diet and environmental factors, may contribute to the development of cancer via the modulation of signaling pathways of intestinal epithelial cells. Multiple mutations over many years are required for the occurrence of abnormal growth that leads to colon cancer [29, 30].

Artificially induced (by a specific carcinogen) tumors in laboratory animals provide an opportunity to investigate various aspects of carcinogenesis that cannot be effectively studied in the human body directly [31–33].

\* Correspondence: [o.lynachak@gmail.com](mailto:o.lynachak@gmail.com)

<sup>1</sup>Taras Shevchenko National University of Kyiv, 64 Volodymyrska Str, 01601 Kyiv, Ukraine

Full list of author information is available at the end of the article

Therefore, a significant number of the experimental models of tumorigenesis in various organs were developed. The dimethylhydrazine model is an effective tool to study the features of intestinal carcinogenesis under the action of therapeutic agents. Morphological changes in rat intestine caused by the 1,2-dimethylhydrazine (DMH) are similar to those that occur during the colon cancer development in human tissues [32, 34].

The aim of this work was to study and analyze the antitumor activity of pristine  $C_{60}$  fullerene aqueous solution ( $C_{60}$ FAS) compared with the effect of pyrrole derivative 1-(4-Cl-benzyl)-3-Cl-4-( $CF_3$ -fenylamino)-1H-pyrrol-2.5-dione (MI-1) and the most commonly used 5-fluorouracil (5-FU) drug on the DMH-induced colon cancer model in rats.

## Methods

A highly stable reproducible  $C_{60}$ FAS in concentration 0.15 mg/ml was prepared according to the protocol [7, 8].

Small-angle X-ray scattering (SAXS) experiments were carried out on instrument with high-intensity microfocus rotating Cu anode X-ray generator in the laboratory for advanced studies of membrane proteins (Moscow Institute of Physics and Technology, Dolgoprudniy, Russia), using a standard transmission configuration. An X-ray wavelength of  $\lambda = 1.54 \text{ \AA}$  was used, resulting a momentum transfer  $Q$  in the range of  $0.007\text{--}0.2 \text{ \AA}^{-1}$ , where  $Q = (4\pi/\lambda) \times \sin(\theta/2)$  and  $\theta$  is the scattering angle. The samples studied were placed in borosilicate capillaries of 1.5-mm diameter and 0.01-mm wall thickness (W. Muller, Berlin, Germany). Water was used as a buffer sample. Center of beam line and conversation channel to value of module  $q$ -vector was done using silver behenate.

Pyrrole derivative 1-(4-Cl-benzyl)-3-Cl-4-( $CF_3$ -fenylamino)-1H-pyrrole-2.5-dione (MI-1) was synthesized by the ChemBioCenter in Taras Shevchenko National University of Kyiv [35, 36].

2,4-Dihydroxy-5-fluoropyrimidine (5-FU; "Darnitsa," Ukraine) was used in experiments.

The study was conducted on 60 white male rats of the "Wistar" line weighing 180–200 g. The animals were kept under standard conditions in the vivarium of the ESC "Institute of Biology and Medicine," Taras Shevchenko National University of Kyiv. Animals had free access to food and water. All experiments were conducted in accordance with the international principles of the European Convention for the protection of vertebrate animals under a control of the Bio-Ethics Committee of the abovementioned institution.

Colorectal cancer was induced by DMH (Sigma-Aldrich, USA), which was administered weekly for 20 weeks at a dose of 20 mg/kg (the dose and duration of administration are sufficient for the induction and subsequent development of colorectal cancer in rats) [37].


Starting from the 21 weeks of the experiment, the animals were divided into four groups: I—control (animals were given subcutaneous injections of saline weekly); II—animals were treated by subcutaneous injections of  $C_{60}$ FAS at a dose of 2.0 mg/kg weekly; III—animals were treated by subcutaneous injections of 5-FU at a dose of 45 mg/kg weekly; IV—animals were given MI-1 intragastric at a dose of 2.7 mg/kg daily. After 27 weeks, the animals were submitted to euthanasia with  $CO_2$ . Immediately after euthanasia, the intestine was removed (from the cecum to the anus) and was opened with scissors in the antimesenteric border and stretched in Styrofoam plates for cleaning with 0.9% NaCl. The number, location, and area of the neoformations were determined by special procedures [38]. The tumors were excised and fixed in 10% neutral buffered formalin and then subjected to standard histological processing and staining with hematoxylin and eosin. Slides were analyzed using a light microscope Olympus BX-41 (Germany). The obtained results were treated by conventional methods of statistics using StatPlus2009 software.

Modeling of the coordination complex of  $C_{60}$  fullerene with Fe ion was accomplished using the  $C_{60}(OH)_{24}$  fullerenol model of the  $C_{60}$  molecule. The initial structure of  $C_{60}(OH)_{24}Fe(H_2O)_3$  was built by creating its geometry similar to the well-established geometry of the  $Fe(H_2O)_3$  octahedral cluster in water [39]. The spatial structure of  $C_{60}(OH)_{24}Fe(H_2O)_3$  was preliminary optimized by means of the MM+ molecular mechanics method in HyperChem 8.0. The final optimization was made by means of the PM6 method in Gaussian09W.

## Results and Discussion

Since the  $C_{60}$  fullerene particles size directly correlates with their biodistribution and toxicity [3, 15, 16], SAXS study of  $C_{60}$ FAS was performed.

The experimental SAXS curve of  $C_{60}$ FAS is shown in Fig. 1. The absence of specific peculiarities on the curve



suggests that the particles are polydisperse in size. It is in a good agreement with probe microscopy data [40, 41]. At sufficiently small  $q$  values ( $qR_g < 1$ ), the scattered intensity can be described by the Guinier approximation

$$I(q) = I(0) \exp\left\{-\left(qR_g\right)^{2/3}\right\}$$

with two parameters, which are the forward scattered intensity,  $I(0)$ , and the apparent radius of gyration,  $R_g$ . The found gyration radius of clusters,  $R_g$ , is about 20 nm. For spherical homogeneous approximation in the case of  $C_{60}$ FAS [6, 40, 42, 43], the  $C_{60}$  fullerene nanoparticle size can be estimated as  $2 \times (5/3)^{1/2} \times R_g$ , which gives the effective diameter about 52 nm.

All experimental rats had tumors in the colon. The vast majority of tumors were detected in the descending colon, which is typical for this model of carcinogenesis [32]. Neoplasms had different sizes and shapes (flat, protruding, raised, recessed, granular, and agranular) with exophytic and entophytic types of growth. From the histological studies, the adenoma and adenocarcinoma were found (data not shown). Rats treated by  $C_{60}$ FAS mainly had adenoma.

Table 1 shows the average size of tumors, the average number of tumors, and the total area of lesions of different parts of the colon under the action of DMH.

Introduction of  $C_{60}$ FAS caused the reduction of the number of tumors in the cecum by 57% and the total lesion area by 65% (Table 1). Under the 5-FU action, only the downward trend of these rates was observed.

In the colon, the number of tumors has reduced by 28% and the total lesions area by 40% under the  $C_{60}$ FAS action; it was close to the 5-FU effects (Table 1). A tendency to the reduction of the average area of tumors was also observed.

In the rectum, the number of tumors had demonstrated a tendency to reduction and the total lesions area had decreased by 33% under the  $C_{60}$ FAS action (Table 1).

Under the action of traditional anticancer drug, 5-FU, only a tendency to decrease the average tumor area and the total lesion area was noted.

In total, in the colon,  $C_{60}$ FAS reduced the number of tumors by 31% and the total lesion area by 42% (Table 1). Nearly the same quantitative changes had also occurred under the action of 5-FU, viz. the tumor area decreased by 28% and the total lesion area by 43%.

The antitumor effect of MI-1 was similar to  $C_{60}$ FAS and 5-FU: the average number of tumors, tumor size, and total lesions area were reduced (Table 1). Note that MI-1 is characterized by low toxicity in the gastrointestinal tract and hematopoietic organs [44, 45].

Thus, therapeutic administration of  $C_{60}$ FAS, 5-FU, and MI-1 leads to a reduction of the number of DMH-induced tumors and colon lesion area in rats. MI-1 and 5-FU drugs (the latter is related to antimetabolites and pyrimidine antagonists, whose antitumor effect manifests itself as a result of 5-fluorouracil converted to fluorodeoxyuridine monophosphate, fluorodeoxyuridine triphosphate, and fluorouridine triphosphate [46]) violate DNA synthesis and, as a consequence, inhibit cell division. The mechanism of  $C_{60}$  fullerene action is different and can be related to its antioxidant effect [47, 48] that causes the epigenetic changes in tumor cells, which inhibit their further growth. As a result of the DMH metabolism in the liver, the formation of electrophilic diazonium ions occurs [32], which causes an oxidative stress.  $C_{60}$  fullerene, being a powerful antioxidant, is able to prevent the progression of tumors at an early stage. Based on the fact that MI-1 and  $C_{60}$  fullerene have different mechanisms of action, the observed effectiveness of their combined action on the colorectal

**Table 1** The effectiveness of 5-FU, MI-1, and  $C_{60}$ FAS at DMH-induced colon cancer ( $M \pm m$ ;  $n = 15$ )

	Parts of the large intestine	Experimental group			
		DMH	DMH + 5-FU	DMH + $C_{60}$ FAS	DMH + MI-1
Average number of tumors, per rat	Cecum	2.8 ± 0.4	1.8 ± 0.3	1.2 ± 0.1*	1.3 ± 0.2*
	Colon	11.5 ± 1.0	9.0 ± 0.4	8.3 ± 0.2*	8.6 ± 0.7*
	Rectum	2.6 ± 0.3	2.8 ± 0.4	2.0 ± 0.3	1.9 ± 0.2
	All parts	16.8 ± 1.0	13.5 ± 0.7	11.5 ± 0.3*	11.8 ± 0.8*
Average area of tumors, mm <sup>2</sup>	Cecum	9.6 ± 1.8	6.4 ± 1.0	9.4 ± 1.7	5.0 ± 1.0*
	Colon	15.0 ± 1.6	9.0 ± 0.5	11.2 ± 0.7	11.6 ± 0.5
	Rectum	22.0 ± 2.1	18.6 ± 2.1	18.4 ± 1.1	16.1 ± 2.0
	All parts	14.5 ± 1.1	10.3 ± 0.5*	12.1 ± 0.6	11.4 ± 0.5*
Total area of tumors, per rat, mm <sup>2</sup>	Cecum	30.5 ± 8.1	11.1 ± 2.0	10.5 ± 1.6*	6.3 ± 1.2*
	Colon	158.9 ± 11.7	79.7 ± 1.8*	95.0 ± 7.8*	100.9 ± 10.3*
	Rectum	51.9 ± 5.1	45.8 ± 5.5	34.6 ± 3.3*	29.2 ± 4.7*
	All parts	241.3 ± 16.4	136.6 ± 6.1*	140.0 ± 10.3*	136.4 ± 12.9*

\* $p < 0.05$  relative to control

carcinogenesis model can therefore be explained, at least in part. Hence, the simultaneous administration of MI-1 and  $C_{60}$  fullerene can potentially increase the effectiveness of anticancer therapy and reduce side effects, reported recently for other  $C_{60}$  fullerene-drug combinations [49, 50]. Let us further discuss the possible mechanism by which the antioxidant effect of  $C_{60}$ FAS may operate in the system investigated in the present work.

It is currently considered that the water-soluble  $C_{60}$  fullerene derivative,  $C_{60}(\text{OH})_{24}$  fulleranol, exerts its protective role against doxorubicin-induced toxicity due to the removal of free iron, forming a stable “fullerenol-iron” complex [51]. Because the cancer cells grow rapidly in response to iron, the formation of colorectal cancer can therefore be inhibited by the removal of free iron in the form of “fullerenol-iron” nanoparticles. Let us further consider the possibility of formation of stable complex between pristine  $C_{60}$  fullerene used in the present work (not containing the  $-\text{OH}$  groups), and the iron ions, which cannot be expected from the very beginning.

It has long been established that the dissolution of pristine  $C_{60}$  fullerene in water is due to the formation of solvation shell around the  $C_{60}$  molecule tightly attached to it [5, 6, 43, 52, 53]. However, recent data have evidenced that the molecular dissolution of the  $C_{60}$  fullerene in water, at least in part, is promoted by the attachment of a certain number of OH groups to the  $C_{60}$  fullerene surface, i.e., the pristine  $C_{60}$  fullerene in water becomes partially hydroxylated [7, 54]. The number of the  $-\text{OH}$  groups attached to the surface is still unknown, but the literature data suggest that the  $C_{60}$  molecule may incorporate 2 to 44 hydroxyls freely migrating around the  $C_{60}$  fullerene surface [55]. On the other hand, the coordination number of the transition metal ions, including the iron ions such as  $\text{Fe}^{+2}$  and  $\text{Fe}^{+3}$ , typically equals to 6. In water, the Fe ions


are coordinated by six water molecules forming regular octahedral. Taking this into account, it can be assumed that the “ $C_{60}$  fullerene-iron” complex may be formed by the coordination of three  $-\text{OH}$  groups on the surface of  $C_{60}$  fullerene and three water molecules from the bulk solution. The corresponding energy-minimized structure of the proposed complex is given in Fig. 2a. The stability of such structure is verified by the fact that the resultant geometry of the coordinated cluster well matches the geometry of the stable Fe octahedral in water (Fig. 2b), i.e., the distance between Fe ion and water oxygen in hydrated ions is close to the same distance in  $C_{60}$  fullerene-iron octahedral ( $\approx 2 \text{ \AA}$ ). We consider that such complexation of Fe to water-soluble pristine  $C_{60}$  fullerene may explain the antioxidant effect of  $C_{60}$ FAS synergistically/additively operating together with doxorubicin [49] or MI-1 in suppression the tumor growth.

## Conclusions

It was found that the administration of pristine  $C_{60}$  fullerene aqueous solution ( $C_{60}$ FAS), 5-fluorouracil (5-FU), and pyrrole derivative 1-(4-Cl-benzyl)-3-Cl-4-(CF<sub>3</sub>-phenylamino)-1H-pyrrol-2,5-dione (MI-1) reduces the number of 1,2-dimethylhydrazine-induced tumors and colon lesion area in rats. The antitumor effects of  $C_{60}$ FAS and MI-1 demonstrated no significant difference but additively operate in tumor suppression on their simultaneous use. These results point out the possibility of the practical application of  $C_{60}$ FAS and MI-1 in the combination therapy of colorectal cancer.

## Abbreviations

5-FU: 5-Fluorouracil; DMH: 1,2-Dimethylhydrazine; MI-1: Pyrrole derivative 1-(4-Cl-benzyl)-3-Cl-4-(CF<sub>3</sub>-phenylamino)-1H-pyrrol-2,5-dione;  $C_{60}$ FAS:  $C_{60}$  fullerene aqueous solution



**Fig. 2** Hydrated iron ion (Fe ion is located in the center of octahedral. Water molecules are located in heights (a); the calculated structure of the “ $C_{60}$  fullerene-iron” complex (b))

**Authors' Contributions**

All authors read and approved the final manuscript.

**Competing Interests**

The authors declare that they have no competing interests.

**Ethics Approval**

All experiments were conducted in accordance with the international principles of the European Convention for the protection of vertebrate animals under a control of the Bio-Ethics Committee of the abovementioned institution.

**Author details**

<sup>1</sup>Taras Shevchenko National University of Kyiv, 64 Volodymyrska Str, 01601 Kyiv, Ukraine. <sup>2</sup>Joint Institute for Nuclear Research, Dubna, Moscow Region, Russia. <sup>3</sup>Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region, Russia. <sup>4</sup>Sevastopol State University, Sevastopol, Crimea, Ukraine. <sup>5</sup>Belgorod State University, 85 Pobedy Str, 308015 Belgorod, Russia. <sup>6</sup>Institute of Chemistry and Biotechnology, Technical University of Ilmenau, 25 Weimarer Str, 98693 Ilmenau, Germany.

Received: 9 November 2016 Accepted: 7 December 2016

Published online: 05 January 2017

**References**

- Prylutskyi YI, Yashchuk VM, Kushnir KM, Golub AA, Kudrenko VA, Prylutska SV, Grynyuk II, Buzaneva EV, Scharff P, Braun T, Matyshevska OP (2003) Biophysical studies of fullerene-based composite for bio-nanotechnology. *Mater Sci Engineer C* 23:109–111
- Hirsch A, Brettreich M, Wudl F (2005) Fullerenes: chemistry and reactions. Wiley Interscience, NY
- Medicinal chemistry and pharmacological potential of fullerenes and carbon nanotubes, series: carbon materials: chemistry and physics (2008) ed. Cataldo F and Da Ros T. Springer, Netherlands
- Anilkumar P, Lu F, Cao L, Luo PG, Liu JH, Sahu S, Tackett NK, Wang Y, Sun YP (2011) Fullerenes for applications in biology and medicine. *Curr Med Chem* 18:2045–2059
- Mchedlov-Petrosyan NO (2013) Fullerenes in liquid media: an unsettling intrusion into the solution chemistry. *Chem Rev* 113:5149–5193
- Yu P, Durov S, Bulavin L, Pogorelov V, Yu A, Yashchuk V, Ogul'chansky T, Buzaneva E, Andrievsky G (1998) Study of structure of colloidal particles of fullerenes in water solution. *Mol Cryst Liq Cryst* 324:65–70
- Prylutskyi YI, Petrenko VI, Ivanov OI, Kyzyma OA, Bulavin LA, Litsis OO, Evstigneev MP, Cherepanov VV, Naumovets AG, Ritter U (2014) On the origin of C<sub>60</sub> fullerene solubility in aqueous solution. *Langmuir* 30:3967–3970
- Ritter U, Prylutskyi YI, Evstigneev MP, Davidenko NA, Cherepanov VV, Senenko AI, Marchenko OA, Naumovets AG (2015) Structural features of highly stable reproducible C<sub>60</sub> fullerene aqueous colloid solution probed by various techniques. *Fuller Nanotube Carbon Nanostr* 23:530–534
- Foley S, Crowley C, Smaih M, Bonfils C, Erlanger BF, Seta P, Larroque C (2002) Cellular localization of a water-soluble fullerene derivative. *Biochem Biophys Res Commun* 294:116–119
- Prylutska SV, Matyshevska OP, Grynyuk II, Prylutskyi YI, Ritter U, Scharff P (2007) Biological effects of C<sub>60</sub> fullerenes *in vitro* and in a model system. *Mol Cryst Liq Cryst* 468:265–274
- Schuetze C, Ritter U, Scharff P, Bychko A, Prylutska S, Rybalchenko V, Yu P (2011) Interaction of N-fluorescein-5-isothiocyanate pyrrolidine-C<sub>60</sub> compound with a model bimolecular lipid membrane. *Mater Sci Engineer C* 31:1148–1150
- Prylutska S, Bilyi R, Overchuk M, Bychko A, Andreichenko K, Stoika R, Rybalchenko V, Yu P, Tsiherkezos NG, Ritter U (2012) Water-soluble pristine fullerenes C<sub>60</sub> increase the specific conductivity and capacity of lipid model membrane and form the channels in cellular plasma membrane. *J Biomed Nanotechnol* 8:522–527
- Prylutska SV, Matyshevska OP, Golub AA, Prylutskyi YI, Potebnya GP, Ritter U, Scharff P (2007) Study of C<sub>60</sub> fullerenes and C<sub>60</sub>-containing composites cytotoxicity *in vitro*. *Mater Sci Engineer C* 27:1121–1124
- Prylutska SV, Grynyuk II, Grebinyk SM, Matyshevska OP, Prylutskyi YI, Ritter U, Siegmund C, Scharff P (2009) Comparative study of biological action of fullerenes C<sub>60</sub> and carbon nanotubes in thymus cells. *Mat-wiss u Werkstofftech* 40:238–241
- Johnston HJ, Hutchison GR, Christensen FM, Aschberger K, Stone V (2010) The biological mechanisms and physicochemical characteristics responsible for driving fullerene toxicity. *Toxicol Sci* 114:162–182
- Aschberger K, Johnston HJ, Stone V, Aitken RJ, Tran CL, Hankin SM, Peters SA, Tran CL, Christensen FM (2010) Review of fullerene toxicity and exposure appraisal of a human health risk assessment, based on open literature. *Regul Toxicol Pharmacol* 58:455–473
- Tolkachov M, Sokolova V, Korolovych V, Yu P, Epple M, Ritter U, Scharff P (2016) Study of biocompatibility effect of nanocarbon particles on various cell types *in vitro*. *Mat-wiss u Werkstofftech* 47:216–221
- Prylutska SV, Burlaka AP, Prylutskyi YI, Ritter U, Scharff P (2011) Pristine C<sub>60</sub> fullerenes inhibit the rate of tumor growth and metastasis. *Exp Oncol* 33:162–164
- Prylutska SV, Burlaka AP, Klymenko PP, Grynyuk II, Prylutskyi YI, Schuetze C, Ritter U (2011) Using water-soluble C<sub>60</sub> fullerenes in anticancer therapy. *Cancer Nanotechnol* 2:105–110
- Golub A, Matyshevska O, Prylutska S, Sysyoyev V, Ped L, Kudrenko V, Radchenko E, Yu P, Scharff P, Braun T (2003) Fullerenes immobilized at silica surface: topology, structure and bioactivity. *J Mol Liq* 105:141–147
- Scharff P, Carta-Abelmann L, Siegmund C, Matyshevska OP, Prylutska SV, Koval TV, Golub AA, Yashchuk VM, Kushnir KM, Prylutskyi YI (2004) Effect of X-ray and UV irradiation of the C<sub>60</sub> fullerene aqueous solution on biological samples. *Carbon* 42:1199–1201
- Davydenko MO, Radchenko EO, Yashchuk VM, Dmytruk IM, Prylutskyi YI, Matyshevska OP, Golub AA (2006) Sensibilization of fullerene C<sub>60</sub> immobilized at silica nanoparticles for cancer photodynamic therapy. *J Mol Liq* 127:145–147
- Jiao F, Liu Y, Qu Y, Li W, Zhou G, Ge CC, Li YF, Sun BY (2010) Studies on anti-tumor and antimetastatic activities of fullerene in a mouse breast cancer model. *Carbon* 48:2231–2243
- Panchuk RR, Prylutska SV, Chumak VV, Skorokhod NR, Lehka LV, Evstigneev MP, Prylutskyi YI, Berger W, Heffeter P, Scharff P, Ritter U, Stoika RS (2015) Application of C<sub>60</sub> fullerene-doxorubicin complex for tumor cell treatment *in vitro* and *in vivo*. *J Biomed Nanotechnol* 11:1139–1152
- Prylutska S, Skivka L, Didenko G, Yu P, Evstigneev M, Potebnya G, Panchuk R, Stoika R, Ritter U, Scharff P (2015) Complex of C<sub>60</sub> fullerene with doxorubicin as a promising agent in antitumor therapy. *Nanoscale Res Lett* 10:499
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. *Cancer J Clin* 65:87–108
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2014) Cancer incidence and mortality worldwide: IARC CancerBase. International Agency for Research on Cancer, Lyon
- Siegel R, Desantis C, Jemal A (2014) Colorectal cancer statistics. *Cancer J Clin* 64:104–117
- Migliore L, Migheli F, Spisni R, Coppede F (2011) Genetics, cytogenetics, and epigenetics of colorectal cancer. *J Biomed Biotechnol* 2011:1–19
- Fredericks E, Dealtry G, Roux S (2015) Molecular aspects of colorectal carcinogenesis: a review. *J Cancer Biol Res* 3:1057
- Kanneganti M, Mino-Kenudson M, Mizoguchi E (2011) Animal models of colitis-associated carcinogenesis. *J Biomed Biotechnol* 2011:1–23
- Perse M, Cerar A (2011) Morphological and molecular alterations in 1,2 dimethylhydrazine and azoxymethane induced colon carcinogenesis in rats. *J Biomed Biotechnol* 4:33–43
- Machado VF, Feitosa MR, da Rocha JJR, Féres O (2016) A review of experimental models in colorectal carcinogenesis. *J Coloproctology* 36:53–57
- Tanaka T (2009) Colorectal carcinogenesis: review of human and experimental animal studies. *J Carcinog* 8:5
- Garmanchuk LV, Denis EO, Nikulina VV, Dzhus OI, Skachkova OV, Rybalchenko VK, Ostapchenko LI (2013) M11—derivative of maleimide inhibits cell cycle progression in tumor cells of epithelial origin. *Biopolym Cell* 29:70–74
- Byelinska IV, Garmanchuk LV, Khranovska NM, Shelest DV, Rybalchenko TV (2016) Effect of maleimide derivative, protein kinases inhibitor, on the morphofunctional state of human neoplastic monoblast cell line U-937. *Res J Pharm, Biol Chem Sci* 7:1898–1905
- Perse M, Cerar A (2005) The dimethylhydrazine induced colorectal tumors in rat—experimental colorectal carcinogenesis. *Radiol Oncol* 39:61–70
- Pozharisski KM (1990) Tumors of the intestines. Pathology of tumors in laboratory animals. IARC, Lyon
- Sham TK, Hastings JB, Perlman ML (1980) Structure and dynamic behavior of transition-metal ions in aqueous solution: an EXAFS study of electron-exchange reactions. *J Am Chem Soc* 102:5904–5906

40. Prylutskyy YI, Buchelnikov AS, Voronin DP, Kostjukov VV, Ritter U, Parkinson JA, Evstigneev MP (2013) C<sub>60</sub> fullerene aggregation in aqueous solution. *Phys Chem Chem Phys* 15:9351–9360
41. Skorkina MY, Sladkova EA, Shamray EA, Cherkashina OV, Evstigneev MP, Buchelnikov AS, Prylutskyy YI, Ritter U (2015) C<sub>60</sub> fullerene affects elastic properties and osmoregulation reactions of human lymphocytes. *Eur Biophys J* 44:493–498
42. Prilutski YI, Durov SS, Yashchuk VN, Ogul'chansky TY, Pogorelov VE, Astashkin YA, Buzaneva EV, Kirghizov YD, Andrievsky GV, Scharff P (1999) Theoretical predictions and experimental studies of self-organization C<sub>60</sub> nanoparticles in water solution and on the support. *Eur Phys J D* 9:341–343
43. Prylutskyy YI, Durov SS, Bulavin LA, Adamenko II, Moroz KO, Geru II, Dihor IN, Scharff P, Eklund PC, Grigorian L (2001) Structure and thermophysical properties of fullerene C<sub>60</sub> aqueous solutions. *Int J Thermophys* 22:943–956
44. Kuznietsova HM, Lynchak OV, Danylov MO, Kotlyar IP, Rybalchenko VK (2013) Effect of dihydropyrrrol and maleimide derivatives on the state of the liver and colon in normal rats and those with colorectal carcinogenesis induced by dimethylhydrazine. *Ukr Biochem J* 85:74–84
45. Byelinska IV, Lynchak OV, Tsyvinska SM, Rybalchenko VK (2015) Morphofunctional state of blood cells after chronic exposure of the protein kinases inhibitor maleimide derivative. *Fiziol Zh* 61:71–77
46. Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. *Nature Rev Cancer* 3:330–338
47. Gharbi N, Pressac M, Hadchouel M, Szwarc H, Wilson SR, Moussa F (2005) C<sub>60</sub> fullerene is a powerful antioxidant *in vivo* with no acute or subacute toxicity. *Nano Lett* 5:2578–2585
48. Prylutka SV, Grynyuk II, Matyshevska OP, Prylutskyy YI, Ritter U, Scharff P (2008) Anti-oxidant properties of C<sub>60</sub> fullerenes *in vitro*. *Fuller Nanotube Carbon Nanostr* 16:698–705
49. Prylutka S, Grynyuk I, Matyshevska O, Yu P, Evstigneev M, Scharff P, Ritter U (2014) C<sub>60</sub> fullerene as synergistic agent in tumor-inhibitory doxorubicin treatment. *Drugs R&D* 14:333–340
50. Grynyuk II, Prylutka SV, Franskevych DV, Trush VA, Sliva TY, Slobodyanik MS, Hurmach VV, Prylutskyy YI, Matyshevska OP, Ritter U (2016) Combined action of C<sub>60</sub> fullerene with dimethyl-N-(benzoyl)amidophosphate or dimethyl-N-(phenylsulfonyl) amidophosphate on leukemia L1210 cells *in silico* and *in vitro*. *Mat-wiss u Werkstofftech* 47:98–104
51. Srdjenovic B, Milic-Torres V, Grujic N, Stankov K, Djordjevic A, Vasovic V (2010) Antioxidant properties of fulleranol C<sub>60</sub>(OH)<sub>24</sub> in rat kidneys, testes, and lungs treated with doxorubicin. *Toxicol Mech Methods* 20:298–305
52. Andrievsky GV, Klochkov VK, Boryduh AB, Dovbeshko GI (2002) Comparative analysis of two aqueous-colloidal solutions of C<sub>60</sub> fullerene with help of FTIR reflectance and UV-vis spectroscopy. *Chem Phys Lett* 364:8–17
53. Wang CI, Hua CC, Chen SA (2014) Dynamic solvation shell and solubility of C<sub>60</sub> in organic solvents. *J Phys Chem B* 118:9964–9973
54. Labille J, Masion A, Ziarelli F, Rose J, Brant J, Villieras F, Pelletier M, Borschneck D, Wiesner MR, Bottero JY (2009) Hydration and dispersion of C<sub>60</sub> in aqueous systems: the nature of water-fullerene interactions. *Langmuir* 25:11232–11235
55. Djordjevic A, Srdjenovic B, Seke M, Petrovic D, Injac R, Mrdjanovic J (2015) Review of synthesis and antioxidant potential of fulleranol nanoparticles. *J Nanomater* 2015:567073

Submit your manuscript to a SpringerOpen<sup>®</sup> journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

---

Submit your next manuscript at ► [springeropen.com](http://springeropen.com)

---